Company Name, Ticker, Competitors, else..

Dyne Therapeutics Inc (NASDAQ: DYN)

Sector • Healthcare Industry • Major Pharmaceutical Preparations

Industry • Major Pharmaceutical Preparations

Sector • Healthcare

Dyne Therapeutics Inc 's

Name: Dyne Therapeutics Inc Comparisons to its Competitors and Market Share - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use/

Competitiveness

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

DYN Sales vs. its Competitors Q2 2026

Comparing the current results to its competitors, Dyne Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, slower than the combined decrease of the DYN's competitors by -6.23 %, recorded in the same quarter.

• List of DYN Competitors

Select the Relationship:

Competition ▼

Select the Category:

Comparison ▼

Competition ▼

Basic Report▼

Revenue Growth Comparisons

Net Income Comparison

Dyne Therapeutics Inc recorded a net loss, as well as most of its competitors.

<< DYN Stock Performance Comparisons

<< See the full list of DYN competitors

*Market share is calculated based on total revenue.

News about Dyne Therapeutics Inc Contracts

Dyne Therapeutics Reports Unprecedented Success in Clinical Trials for Rare Muscular Diseases, Sets Course...

September 3, 2024
Dyne Therapeutics, a biotechnology company dedicated to creating transformative therapies for patients with serious muscle diseases, has announced significant advancements across multiple clinical programs. The company is reporting groundbreaking data from its Phase 1/2 DELIVER trial of DYNE-251 for Duchenne muscular dystrophy (DMD), demonstrating unprecedented dystrophin expression and functional improvement. Additionally, Dyne announced positive updates from its ongoing preclinical and clinical studies for facioscapulohumeral muscular dystrophy (FSHD) and myotonic dystrophy type 1 (DM1), respectively. Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular DystrophyIn a recent press release, Dyne Therapeu...

Dyne Therapeutics FORCE Platform Shows Promise in Delivering Enzyme Replacement Therapy for Pompe Disease

June 24, 2024
Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe DiseaseWALTHAM, Mass., June 24, 2024 - Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company, has announced new preclinical data that showcase the potential of their FORCE platform to deliver enzyme replacement therapy (ERT) to cardiac and skeletal muscles as well as the central nervous system (CNS) in Pompe disease. The data was presented at the New Directions in Biology and Disease of Skeletal Muscle Conference, which took place from June 23-26 in Fort Lauderdale, FL.Pompe disease is a rare and progressive muscular disord...

DYN's Stock Performance relative to its Competitors

Publicly Traded Peers of Dyne Therapeutics Inc

Zyversa Therapeutics Inc
Share Performance

-41.76%

One Year

Zyversa Therapeutics Inc

Profile

Zyversa Therapeutics Inc's business model revolves around developing innovative therapies and treatments for various medical conditions.

More about Zyversa Therapeutics Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 0.801 mill.	$ - mill.	$ -24.489 mill.

Keros Therapeutics Inc
Share Performance

-26.16%

One Year

Keros Therapeutics Inc

Profile

Keros Therapeutics Inc's business model is focused on the development of therapeutics to address significant unmet needs in various diseases by targeting specific protein elements within the cell signaling pathways.

More about Keros Therapeutics Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 230.278 mill.	$ - mill.	$ -83.159 mill.

Inozyme Pharma Inc
Share Performance

-9.30%

One Year

Inozyme Pharma Inc

Profile

Inozyme Pharma Inc is a biopharmaceutical company that focuses on developing and commercializing novel therapies for the treatment of rare and life-threatening mineral metabolic disorders. The company aims to leverage its expertise in the biology of enzymes and rare diseases to develop innovative therapeutics that can address the underlying cause of these disorders. Inozyme Pharma pursues partnerships and collaborations to advance their pipeline of potential therapies and bring them to market efficiently.

More about Inozyme Pharma Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 257.114 mill.	$ - mill.	$ -106.716 mill.

Fulcrum Therapeutics Inc
Share Performance

+1.06%

This Quarter

Fulcrum Therapeutics Inc

Profile

Fulcrum Therapeutics Inc operates as a biopharmaceutical company that focuses on developing personalized therapies for genetically defined diseases. Their business model involves leveraging their proprietary product engine to identify and target specific gene regulatory networks to address the root causes of diseases.

More about Fulcrum Therapeutics Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 290.566 mill.	$ - mill.	$ -84.999 mill.

Editas Medicine Inc
Share Performance

-10.33%

30 Days

Editas Medicine Inc

Profile

Editas Medicine Inc.'s business model revolves around developing and commercializing transformative genome editing technologies to treat serious diseases.

More about Editas Medicine Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 320.903 mill.	$ 47.005 mill.	$ -73.949 mill.

23 more competitors available

Sources: Dyne Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Friday, September 18, 2026 10:44 AM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Dyne Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.